人工智能时代的免疫工程:从基础研究到临床转化

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Meng Zhu, Andy Tay, Xianlei Li
{"title":"人工智能时代的免疫工程:从基础研究到临床转化","authors":"Meng Zhu,&nbsp;Andy Tay,&nbsp;Xianlei Li","doi":"10.1002/adtp.202500087","DOIUrl":null,"url":null,"abstract":"<p>Artificial intelligence (AI) plays a pivotal role in advancing immune engineering, a field aimed at developing personalized therapies for cancer, autoimmune diseases, and infections. AI is overcoming significant challenges in immune engineering, such as immune system complexity, patient-specific variability, and the dynamic interactions within the immune microenvironment. This perspective highlights how AI is bridging the gap between laboratory research and clinical application through three major pillars: 1) Mechanistic Decoding, where AI integrates multi-omics data to understand immune system complexity and predict molecular interactions; 2) Therapeutic Innovation, where AI designs personalized immunotherapies, such as optimizing antibody-antigen binding and immune receptor dynamics; and 3) Clinical Acceleration, where AI enhances clinical trial designs, speeds up drug development, and adjusts therapies in real-time based on patient responses. Further discussion addresses algorithmic bias, data privacy, and the need for global standards in AI-powered decision-making, ethical and regulatory challenges. AI is not only enabling breakthroughs in immune engineering but also paving the way for customized immune-based therapies. It ensures that the technologies are applied responsibly and equitably in clinical practice.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 9","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immuno-Engineering in the AI Era: From Fundamental Research to Clinical Translation\",\"authors\":\"Meng Zhu,&nbsp;Andy Tay,&nbsp;Xianlei Li\",\"doi\":\"10.1002/adtp.202500087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Artificial intelligence (AI) plays a pivotal role in advancing immune engineering, a field aimed at developing personalized therapies for cancer, autoimmune diseases, and infections. AI is overcoming significant challenges in immune engineering, such as immune system complexity, patient-specific variability, and the dynamic interactions within the immune microenvironment. This perspective highlights how AI is bridging the gap between laboratory research and clinical application through three major pillars: 1) Mechanistic Decoding, where AI integrates multi-omics data to understand immune system complexity and predict molecular interactions; 2) Therapeutic Innovation, where AI designs personalized immunotherapies, such as optimizing antibody-antigen binding and immune receptor dynamics; and 3) Clinical Acceleration, where AI enhances clinical trial designs, speeds up drug development, and adjusts therapies in real-time based on patient responses. Further discussion addresses algorithmic bias, data privacy, and the need for global standards in AI-powered decision-making, ethical and regulatory challenges. AI is not only enabling breakthroughs in immune engineering but also paving the way for customized immune-based therapies. It ensures that the technologies are applied responsibly and equitably in clinical practice.</p>\",\"PeriodicalId\":7284,\"journal\":{\"name\":\"Advanced Therapeutics\",\"volume\":\"8 9\",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://advanced.onlinelibrary.wiley.com/doi/10.1002/adtp.202500087\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://advanced.onlinelibrary.wiley.com/doi/10.1002/adtp.202500087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

人工智能(AI)在推进免疫工程方面发挥着关键作用,免疫工程是一个旨在开发针对癌症、自身免疫性疾病和感染的个性化疗法的领域。人工智能正在克服免疫工程中的重大挑战,如免疫系统复杂性、患者特异性变异性以及免疫微环境内的动态相互作用。这一观点强调了人工智能如何通过三个主要支柱弥合实验室研究和临床应用之间的差距:1)机械解码,人工智能整合多组学数据,以了解免疫系统的复杂性并预测分子相互作用;2)治疗创新,AI设计个性化免疫疗法,如优化抗体-抗原结合和免疫受体动力学;3)临床加速,即人工智能增强临床试验设计,加快药物开发,并根据患者反应实时调整治疗方法。进一步的讨论涉及算法偏见、数据隐私、人工智能驱动决策的全球标准需求、道德和监管挑战。人工智能不仅使免疫工程取得突破,而且为定制免疫疗法铺平了道路。它确保这些技术在临床实践中得到负责任和公平的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Immuno-Engineering in the AI Era: From Fundamental Research to Clinical Translation

Immuno-Engineering in the AI Era: From Fundamental Research to Clinical Translation

Immuno-Engineering in the AI Era: From Fundamental Research to Clinical Translation

Immuno-Engineering in the AI Era: From Fundamental Research to Clinical Translation

Artificial intelligence (AI) plays a pivotal role in advancing immune engineering, a field aimed at developing personalized therapies for cancer, autoimmune diseases, and infections. AI is overcoming significant challenges in immune engineering, such as immune system complexity, patient-specific variability, and the dynamic interactions within the immune microenvironment. This perspective highlights how AI is bridging the gap between laboratory research and clinical application through three major pillars: 1) Mechanistic Decoding, where AI integrates multi-omics data to understand immune system complexity and predict molecular interactions; 2) Therapeutic Innovation, where AI designs personalized immunotherapies, such as optimizing antibody-antigen binding and immune receptor dynamics; and 3) Clinical Acceleration, where AI enhances clinical trial designs, speeds up drug development, and adjusts therapies in real-time based on patient responses. Further discussion addresses algorithmic bias, data privacy, and the need for global standards in AI-powered decision-making, ethical and regulatory challenges. AI is not only enabling breakthroughs in immune engineering but also paving the way for customized immune-based therapies. It ensures that the technologies are applied responsibly and equitably in clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advanced Therapeutics
Advanced Therapeutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.10
自引率
2.20%
发文量
130
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信